The Life Sciences Practice Group at Hill Wallack LLP focuses on the comprehensive representation of established and start-up Life Science companies. Leveraging Hill Wallack’s other practice areas to ensure a comprehensive team, the Life Sciences group provides representation in connection with intellectual property, technology transfer and university spin-outs, venture capital and finance, regulatory and compliance, and mergers and acquisitions.
Hill Wallack LLP represents Life Science companies in the following industries:
- Medical Devices
- Clinical Research
What We Do
Hill Wallack LLP recognizes that companies in the Life Sciences industry face both unique challenges such as complicated regulatory dynamics as well as unique funding opportunities from special incubator, venture capital and public funding sources. They are however, at their core, businesses with the same challenges and needs of every other business venture. Hill Wallack LLP combines our unique connection to the scientific community with an experienced team of commercial and business legal professionals to provide a comprehensive solution to the legal needs of Life Sciences companies.
- Negotiation of research and biological transfer agreements with universities regarding funding of research by venture capital investors.
- Local counsel to domestic and Asian generic pharmaceutical companies in intellectual property litigation in the U.S. District Court, District of New Jersey.
- Negotiation of patent license agreements between start-up life science companies and universities.
- Representation of clinical research organizations (CROs) in partnership agreements concerning clinical safety and pharmacovigilance services.
- Preparation and negotiation of stock purchase, transfer and vesting agreements between shareholders of life science companies.
- Representation in all aspects of real estate matters, including financing, acquisition, leasing, environmental, zoning, construction and disposition.
- Prosecute patent applications and advise Life Sciences clients on various Intellectual Property/FDA issues and matters, designed and administered sophisticated competitive investigation and analysis surveys as to potential Section 505(j) ANDA generic entries (Paragraphs III and IV pathways) and “paper NDAs” under Section 505(b)(2) and comprehensive prior art and competitive pipeline landscape surveys and analysis reports to C-level management for implementation of clients’ global patent/product strategies.
- Institute and prosecute USPTO inter parties reviews (IPRs) before the PTAB challenging biotech patent validity; monitor and counsel key management on competitor IP litigation, including challenges of validity and enforceability of pharmaceutical and bioactive NCEs, compounds and compositions; administer and author comprehensive prior art search analyses and reports directed towards invalidation, freedom to operate and novelty (patentability) and provided counsel regarding management of patent portfolios and extensions of protection.
- Negotiation of licensing, biological transfer, co-development and joint venture agreements between Life Science companies and third parties.